ATE398180T1 - Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna - Google Patents

Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna

Info

Publication number
ATE398180T1
ATE398180T1 AT02731102T AT02731102T ATE398180T1 AT E398180 T1 ATE398180 T1 AT E398180T1 AT 02731102 T AT02731102 T AT 02731102T AT 02731102 T AT02731102 T AT 02731102T AT E398180 T1 ATE398180 T1 AT E398180T1
Authority
AT
Austria
Prior art keywords
apolipoprotein
methods
apobec
modifying
mrna
Prior art date
Application number
AT02731102T
Other languages
English (en)
Inventor
Harold Smith
Yan Yang
Mark Sowden
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE398180T1 publication Critical patent/ATE398180T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02731102T 2001-02-27 2002-02-26 Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna ATE398180T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27185601P 2001-02-27 2001-02-27

Publications (1)

Publication Number Publication Date
ATE398180T1 true ATE398180T1 (de) 2008-07-15

Family

ID=23037380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731102T ATE398180T1 (de) 2001-02-27 2002-02-26 Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna

Country Status (7)

Country Link
US (2) US20040115184A1 (de)
EP (1) EP1392846B1 (de)
JP (1) JP2004521625A (de)
AT (1) ATE398180T1 (de)
CA (1) CA2439472A1 (de)
DE (1) DE60227069D1 (de)
WO (1) WO2002068676A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
US20050112555A1 (en) * 2003-09-03 2005-05-26 Smith Harold C. Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20100100976A1 (en) * 2006-08-28 2010-04-22 University Of Rochester Methods and compositions related to apobec-1 expression
US9084762B2 (en) 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
JP2014523249A (ja) * 2011-07-12 2014-09-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ マイクロユートロフィンポリペプチドと方法
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592381A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Krebsimpfstoff
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (de) 2018-07-09 2022-07-20 The Broad Institute Inc. Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
AU2019336245B2 (en) 2018-09-07 2026-02-26 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
EP3850088A4 (de) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Zusammensetzungen und verfahren zur verbesserten basisbearbeitung
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN114040977B (zh) 2019-01-31 2024-09-03 比姆医疗股份有限公司 非靶脱氨反应减低的核碱基编辑器和用于定性核碱基编辑器的测定
AU2020223314A1 (en) 2019-02-13 2021-08-12 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
EP3942043A2 (de) 2019-03-19 2022-01-26 The Broad Institute, Inc. Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021056302A1 (en) * 2019-09-26 2021-04-01 Syngenta Crop Protection Ag Methods and compositions for dna base editing
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
US12576151B2 (en) 2020-09-25 2026-03-17 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
CN117729931A (zh) * 2021-05-14 2024-03-19 比姆医疗股份有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
CN113234745B (zh) * 2021-06-11 2021-11-02 山东祥维斯生物科技股份有限公司 利用PTD-Tat实现海洋微生物低温脂肪酶基因的跨膜转导方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468022A (en) * 1994-06-14 1995-11-21 Massachusetts Institute Of Technology Sample tube identification flag
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5866333A (en) * 1996-03-01 1999-02-02 Regents Of The University Of California Screening methods to detect mRNA targets of editing enzymes
US5747319A (en) * 1996-07-25 1998-05-05 Incyte Pharmaceuticals, Inc. Human mRNA editing enzyme
JP2002512597A (ja) * 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
US5804185A (en) * 1997-03-13 1998-09-08 Incyte Pharmaceuticals, Inc. RNA editing enzyme REE-2
FR2773079B1 (fr) * 1997-12-30 2002-05-17 Itzik Harosh Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
WO2002081504A2 (en) * 2001-04-06 2002-10-17 Thomas Jefferson University Multimerization of hiv-1 vif protein as a therapeutic target
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
WO2005024422A2 (en) * 2003-05-23 2005-03-17 Oregon Health & Science University Methods for identifying inhibitors
US20050112555A1 (en) * 2003-09-03 2005-05-26 Smith Harold C. Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof

Also Published As

Publication number Publication date
US20040115184A1 (en) 2004-06-17
DE60227069D1 (de) 2008-07-24
WO2002068676A2 (en) 2002-09-06
EP1392846A2 (de) 2004-03-03
EP1392846A4 (de) 2005-09-21
JP2004521625A (ja) 2004-07-22
US20100297219A1 (en) 2010-11-25
CA2439472A1 (en) 2002-09-06
EP1392846B1 (de) 2008-06-11
WO2002068676A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
DE60227069D1 (de) VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODIFIKATION DER BEARBEITUNG VON APOLIPOPROTEIN B-mRNA
AU4185001A (en) Protein scaffolds for antibody mimics and other binding proteins
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE439592T1 (de) Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2004101740A3 (en) Clotting factor-fc chimeric proteins to treat hemophilia
DE69917716D1 (de) Protein-deamiderendes Enzym, dafür kodierendes Gen, Verfahren zur Herstellung und Verwendung davon
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DE69723074D1 (de) Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
IL115792A0 (en) Al-1 neurothophic factor
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
WO2002064840A3 (en) Methods for identifying compounds that inhibit or reduce ptp1b expression
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
Verhoeven et al. Hepatic lipase mRNA is expressed in rat and human steroidogenic organs
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
ATE501730T1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties